0222 GMT - IHH Healthcare's Turkish unit is likely to maintain its growth momentum despite political uncertainty there, Maybank Investment Bank analysts Nur Natasha Ariza and Yin Shao Yang say in a note. While accounting adjustments related to hyperinflation may weigh on reported earnings amid the Turkish lira's depreciation, core earnings should remain resilient, they say. The Acibadem unit benefits from foreign-currency-denominated medical tourism and steady private healthcare spending, they say. Contributing 30% of IHH's 2024 revenue, the Turkey business is projected to see 9% Ebitda growth in 2025, helped partly by stable in-patient volumes, they add. The analysts remain positive on Acibadem's non-lira income and IHH's other key segments. Maybank maintains a buy rating on IHH and keeps its target price at MYR7.97. Shares are unchanged at MYR6.91. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 22:22 ET (02:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.